Genor Biopharma Holdings (HKSE:06998) Days Payable : 71,551.41 (As of Jun. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Genor Biopharma Holdings Days Payable?

Genor Biopharma Holdings's average Accounts Payable for the six months ended in Jun. 2024 was HK$147.4 Mil. Genor Biopharma Holdings's Cost of Goods Sold for the six months ended in Jun. 2024 was HK$0.4 Mil. Hence, Genor Biopharma Holdings's Days Payable for the six months ended in Jun. 2024 was 71,551.41.

The historical rank and industry rank for Genor Biopharma Holdings's Days Payable or its related term are showing as below:

HKSE:06998' s Days Payable Range Over the Past 10 Years
Min: 2066.58 Med: 7920.65 Max: 50966.08
Current: 32494.84

During the past 7 years, Genor Biopharma Holdings's highest Days Payable was 50966.08. The lowest was 2066.58. And the median was 7920.65.

HKSE:06998's Days Payable is ranked better than
97.87% of 704 companies
in the Biotechnology industry
Industry Median: 120.33 vs HKSE:06998: 32494.84

Genor Biopharma Holdings's Days Payable increased from Jun. 2023 (0.00) to Jun. 2024 (71,551.41). It may suggest that Genor Biopharma Holdings delayed paying its suppliers.

Genor Biopharma Holdings Days Payable Historical Data

The historical data trend for Genor Biopharma Holdings's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genor Biopharma Holdings Days Payable Chart

Genor Biopharma Holdings Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Days Payable

Get a 7-Day Free Trial

13,267.06

50,966.08

31,016.84

Genor Biopharma Holdings Semi-Annual Data
	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Days Payable	Get a 7-Day Free Trial							107,265.63	-	-	71,551.41	19,673.03

Competitive Comparison of Genor Biopharma Holdings's Days Payable

For the Biotechnology subindustry, Genor Biopharma Holdings's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Genor Biopharma Holdings's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genor Biopharma Holdings's Days Payable distribution charts can be found below:

* The bar in red indicates where Genor Biopharma Holdings's Days Payable falls into.

Save Embed

;

Save Embed

;

Genor Biopharma Holdings Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Genor Biopharma Holdings's Days Payable for the fiscal year that ended in Dec. 2023 is calculated as

	Days Payable (A: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2022 )	+	Accounts Payable (A: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2023 )	*	Days in Period
=	( (147.583	+	154.946)	/	2 )	/	0	*	365
=	151.2645					/	0	*	365
=	N/A

Genor Biopharma Holdings's Days Payable for the quarter that ended in Jun. 2024 is calculated as:

	Days Payable (Q: Jun. 2024 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Dec. 2023 )	+	Accounts Payable (Q: Jun. 2024 ))	/	count )	/	Cost of Goods Sold (Q: Jun. 2024 )	*	Days in Period
=	( (154.946	+	139.885)	/	2 )	/	0.376	*	365 / 2
=	147.4155					/	0.376	*	365 / 2
=	71,551.41

Genor Biopharma Holdings Days Payable Related Terms

Thank you for viewing the detailed overview of Genor Biopharma Holdings's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Genor Biopharma Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genor Biopharma Holdings Ltd (HKSE:06998) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

67N:Germany

Address

690 Bibo Road, Room 401-17, Building 6, Pudong New District, Shanghai, CHN, 201203

Website

https://www.genorbio.com

Genor Biopharma Holdings Ltd is a commercial-ready biopharmaceutical company focusing on developing and commercializing oncology and autoimmune drugs. The company is focused on therapeutic areas with substantial unmet medical needs in oncology, autoimmune, and other chronic diseases. Its key drug candidates include GB491 (lerociclib), a differentiated oral CDK4/6 inhibitor; GB221, a novel HER2 mAb drug candidate; geptanolimab (GB226), GB492, a STING agonist expected to exert synergistic effects in combination with GB226; GB242, an infliximab (Remicade) biosimilar; and GB223, a RANKL, and others.

Executives

Forebright New Opportunities Fund, L.p.	2101 Beneficial owner
Forbright Global Limited	2201 Interest of corporation controlled by you
Fnof Gp Limited	2201 Interest of corporation controlled by you
Deg – Deutsche Investitions- Und Entwicklungsgesellschaft Mbh	2101 Beneficial owner
Hsg Growth V Holdco Q, Ltd.	2101 Beneficial owner
Hsg Holding Limited	2201 Interest of corporation controlled by you
Snp China Enterprises Limited	2201 Interest of corporation controlled by you
Hongshan Capital Growth Fund Management I, L.p.	2201 Interest of corporation controlled by you
Shen Nan Peng	2201 Interest of corporation controlled by you
Hongshan Capital Growth Fund I, L.p.	2101 Beneficial owner
Hongshan Capital Growth Fund V, L.p.	2201 Interest of corporation controlled by you
Hsg Growth V Management, L.p.	2201 Interest of corporation controlled by you
Hongshan Capital Management I, L.p.	2201 Interest of corporation controlled by you
Hongshan Capital I, L.p.	2101 Beneficial owner
Ni Xin	2101 Beneficial owner

Genor Biopharma Holdings Headlines

No Headlines